These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12208797)

  • 1. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women.
    Decensi A; Omodei U; Robertson C; Bonanni B; Guerrieri-Gonzaga A; Ramazzotto F; Johansson H; Mora S; Sandri MT; Cazzaniga M; Franchi M; Pecorelli S
    Circulation; 2002 Sep; 106(10):1224-8. PubMed ID: 12208797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
    Decensi A; Bonanni B; Baglietto L; Guerrieri-Gonzaga A; Ramazzotto F; Johansson H; Robertson C; Marinucci I; Mariette F; Sandri MT; Daldoss C; Bianco V; Buttarelli M; Cazzaniga M; Franchi D; Cassano E; Omodei U
    Clin Cancer Res; 2004 Jul; 10(13):4389-97. PubMed ID: 15240527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS).
    Taylor HS; Tal A; Pal L; Li F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Du W; Hodis HN; Lobo RA; Manson JE; Merriam GR; Miller VM; Naftolin F; Neal-Perry G; Santoro NF; Harman SM
    JAMA Intern Med; 2017 Oct; 177(10):1471-1479. PubMed ID: 28846767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women.
    Yilmazer M; Fenkci V; Fenkci S; Sonmezer M; Aktepe O; Altindis M; Kurtay G
    Maturitas; 2003 Dec; 46(4):245-53. PubMed ID: 14625121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.
    Lazzeroni M; Macis D; Decensi A; Gandini S; Sandri MT; Serrano D; Guerrieri-Gonzaga A; Johansson H; Mora S; Daldoss C; Omodei U; Bonanni B
    Ecancermedicalscience; 2008; 2():67. PubMed ID: 22275964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women.
    Sumino H; Ichikawa S; Kasama S; Takahashi T; Kumakura H; Takayama Y; Kanda T; Kurabayashi M
    Atherosclerosis; 2006 Dec; 189(2):436-42. PubMed ID: 16469323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women.
    Shifren JL; Rifai N; Desindes S; McIlwain M; Doros G; Mazer NA
    J Clin Endocrinol Metab; 2008 May; 93(5):1702-10. PubMed ID: 18303079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
    Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of transdermal estradiol and oral conjugated equine estrogen on C-reactive protein in retinoid-placebo trial in healthy women.
    Wakatsuki A; Okatani Y; Fukaya T
    Circulation; 2003 May; 107(18):e127-8; author reply e127-8. PubMed ID: 12742976
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women.
    Rabbani LE; Seminario NA; Sciacca RR; Chen HJ; Giardina EG
    J Am Coll Cardiol; 2002 Dec; 40(11):1991-9. PubMed ID: 12475460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study.
    Crandall CJ; Hovey KM; Andrews C; Cauley JA; Stefanick M; Shufelt C; Prentice RL; Kaunitz AM; Eaton C; Wactawski-Wende J; Manson JE
    Menopause; 2017 Oct; 24(10):1145-1153. PubMed ID: 28697036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women.
    Yasui T; Uemura H; Tomita J; Umino Y; Yamada M; Kuwahara A; Matsuzaki T; Maegawa M; Miura M; Irahara M
    Menopause; 2006; 13(4):651-9. PubMed ID: 16837887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women.
    Wakatsuki A; Ikenoue N; Shinohara K; Watanabe K; Fukaya T
    Arterioscler Thromb Vasc Biol; 2004 Mar; 24(3):571-6. PubMed ID: 14699021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers.
    Blondon M; van Hylckama Vlieg A; Wiggins KL; Harrington LB; McKnight B; Rice KM; Rosendaal FR; Heckbert SR; Psaty BM; Smith NL
    J Thromb Haemost; 2014 Jun; 12(6):879-86. PubMed ID: 24628832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: The KEEPS trial.
    El Khoudary SR; Venugopal V; Manson JE; Brooks MM; Santoro N; Black DM; Harman M; Naftolin F; Hodis HN; Brinton EA; Miller VM; Taylor HS; Budoff MJ
    Menopause; 2020 Mar; 27(3):255-262. PubMed ID: 32015261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
    Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
    Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
    Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
    Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA; Farias ML; Andrade AT
    Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.